Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(21 sites)
United States
Children's Hospital of Alabama, Birmingham, Alabama Children's Hospital Los Angeles, Los Angeles, California Children's Hospital of Orange County, Orange, California Lucile Packard Children's Hospital Stanford University, Palo Alto, California UCSF Medical Center-Mission Bay, San Francisco, California Children's Hospital Colorado, Aurora, Colorado Children's National Medical Center, Washington D.C., District of Columbia Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia Lurie Children's Hospital-Chicago, Chicago, Illinois Riley Hospital for Children, Indianapolis, Indiana Dana-Farber Cancer Institute, Boston, Massachusetts C S Mott Children's Hospital, Ann Arbor, Michigan University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota Washington University School of Medicine, St Louis, Missouri NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio Children's Hospital of Philadelphia, Philadelphia, Pennsylvania Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania Saint Jude Children's Research Hospital, Memphis, Tennessee Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas Seattle Children's Hospital, Seattle, Washington Last updated February 2026